Table 3.
Any potential meta-regression pitfall | Yes (n = 57) | No (n = 24) | Odds Ratio (95% CI) |
---|---|---|---|
Published in 2012 | 36 (63%) | 16 (67%) | 0.87 (0.33 to 2.34) |
Journal characteristics | |||
Core clinical journals | 12 (21%) | 7 (29%) | 0.64 (0.22 to 1.85) |
General medical journals | 11 (19%) | 4 (17%) | 1.13 (0.34 to 3.77) |
Impact factor higher than median | 29 (51%) | 11 (46%) | 1.22 (0.47 to 3.11) |
Author characteristics | |||
Affiliated with industry | 5 (9%) | 0 (0%) | 5.13 (0.27 to 96.57) |
Affiliated with biostatistics or epidemiology department | 23 (40%) | 12 (50%) | 0.68 (0.27 to 1.75) |
Ten or more of studies | 53 (93%) | 20 (83%) | 2.61 (0.64 to 10.61) |
Drug intervention | 28 (49%) | 10 (42%) | 1.33 (0.52 to 3.44) |
Binary outcome variable | 25 (44%) | 14 (58%) | 0.57 (0.22 to 1.47) |
Odds ratios are for the comparison of meta-regression analyses with the characteristic as compared to meta-regression analyses without the characteristic. An odds ratio of 2.61 for ‘Ten or more studies’ indicates, for example, that the odds of any potential meta-regression pitfall is 2.61 times higher in meta-regression analyses that include 10 or more studies as compared with meta-regression analyses that include a lower number of studies